(Reuters) – An experimental drug being developed by Roche Holding AG removed amyloid plaques from the brains of Alzheimer’s disease patients in a small early-stage study, according to data published in the Archives of Neurology, the Swiss drugmaker said on Monday.
Read the original here:
... continue reading
MONDAY, Oct. 10 (HealthDay News) — An experimental Alzheimer’s disease drug, gantenerumab, may help lower levels of amyloid plaque in the brains of people with the disease, an early clinical trial indicates.
Read the original post:
New Alzheimer’s Drug Shows Early Promise
Potential to identify at-risk individuals may open the door for preventive therapies Researchers using two brain-imaging technologies have found that apparently normal older individuals with brain deposits of amyloid beta – the primary constituent of the plaques found in the brains of Alzheimer’s disease patients – also had changes in ... continue reading
The protein that forms plaques in the brains of people with Alzheimer’s disease may have its origins in the liver, a new study in mice suggests.
Read more:
Alzheimer’s may start in liver
Researchers have used MRI to detect deterioration of white matter tracts in the brains of older adults at high risk for Alzheimer’s disease. Data suggest that changes in white matter connections may be among the earliest brain changes in Alzheimer’s disease, which may prove important for early detection by noninvasive ... continue reading